The authors of the original article, Clin Sci (Lond) (2023) 137 (9): 727-753, would like to correct their paper. The monoclonal antibody depemokimab described as anti-IL-5R, have been corrected to anti-IL5 in the following statement and in the revised Table 2 provided below.

Table 2
Targeting immune mechanisms in T2 and non-T2 inflammation
TargetApproachNameCompanyPatientsStatus/clinical phase
IgE 
IgE (Cε3 domain-site involved in binding to FcRI) humanized IgG1 MoAb omalizumab Novartis Asthma
urticaria
CRSwNP 
approved 
IgE (Cε3 domain) humanized MoAb ligelizumab Novartis asthma
urticaria 
IgE (M1 segment) humanized MoAb quilizumab Genentech asthma 
IgE (Cε3 domain) humanized MoAb MEDI4212 MedImmune LLC Asthma 
CεmX domain of membrane-bound IgE humanized MoAb FB825 Oneness Biotech Co Asthma 
IL-4/IL-13 
IL4Ra (subunit common to IL-4 and IL-13 receptors human MoAb dupilumab Regeneron/Sanofi atopic dermatitis
asthma CRSwNP
EoE 
approved 
IL-4+IL-13 receptors recombinant IL-4 variant pitrakinra Aerovance atopic dermatitis
asthma 
IL-4+IL-13 2 MoAbs (VAK694+dectrecumab) QBX258 Novartis asthma 
IL-4R suman IgG2 MoAb AMG317 Amgen asthma 
IL-4 humanized MoAb pascolizumab GSK asthma 
IL-4 human MoAb VAK694 Novartis asthma, pollinosis 
IL-4 soluble recombinant IL-4R altrakincept Amgen asthma terminated 
IL-13 humanized MoAb lebrikizumab Lilly atopic dermatitis 
IL-13 human MoAb tralokinumab LeoPharma atopic dermatitis approved 
IL-13 humanized MoAb anrukinzumab Wyeth asthma 
IL-13 humanized MoAb GSK679586 GSK asthma 
IL-13 human MoAb dectrecumab (QAX576) Novartis eosinophilic esophagitis 
IL-13 receptor α1 subunit (IL-13Rα1) human MoAb ASLAN 004 Aslan Pharmaceuticals eczema 
IL-5 
IL-5 humanized IgG1 MoAb mepolizumab GSK asthma,
EGPA
HES
CRSwNP 
approved 
IL-5 humanized MoAb reslizumab Teva asthma approved 
IL-5Ralpha humanized MoAb benralizumab AstraZeneca asthma approved 
IL-5 long acting MoAb depemokimab GSK asthma 
Other molecules regulating T2 inflammation 
TSLP humanized MoAb tezepelumab AstraZeneca/Amgen asthma approved 
TSLP neutralizing antibody fragment (inhaled form) CSJ117 Novartis asthma 2b 
TSLP receptor human MoAb ASP7266 Upstream Bio asthma 
IL-33 MoAb tozorakimab/MEDI3506 AstraZeneca asthma 
IL-33 human MoAb itepekimab Regeneron/Sanofi asthma 
ST2 (IL-33R) MoAb astegolimab Hoffmann-La Roche asthma 2b 
IL-33R MoAb melrilimab (GSK3772847) GSK healthy subjects 
IL-25 MoAb ABM125 Abeome asthma 1/2 
Tryptase tetramers MoAb MTPS9579A Roche/Genetech astma 2a 
CRTh2(PGD2 receptor) antagonist (small molecule) fevipiprant QAW039) Novartis asthma terminated 
CRTh2(PGD2 receptor) antagonist (small molecule) setipiprant Actelion asthma 
IL-9 humanized MoAb enokizumab AstraZeneca/MedImmune asthma 
IL-22 human MoAb fezakinumab Rockefeller University atopic dermatitis 
IL-31 humanized MoAb nemolizumab Galderma atopic dermatitis 
CCR3 (eotaxin receptor) inhibitor (small molecule) GW766944 Glaxo asthma 
Singlec 8 humanized MoAb lirentelimab Allakos Inc. atopic dermatitis eosinophilic esophagitis and duodenitis 2, 3 
Potential targets in non T2 inflammation 
IL-17 humanized MoAb secukinumab Novartis asthma terminated, * 
IL-17RA human MoAb brodalumab Amgen asthma terminated 
C5 humanized MoAb eculizumab Alexion asthma 
CXCR2 receptor antagonist (small molecule) AZD5069 AstraZeneca asthma 
CXCR1/2 receptor antagonist (small molecule) SCH527123 MSD asthma 
IL-6 humanized MoAb tocilizumab Roche asthma small proof‐of‐concept clinical trial, * 
IL-1 rIL-1 receptor antagonist anakinra Sobi asthma 2, * 
IL-1 alpha human MoAb bermekimab Janssen atopic dermatitis 2b 
Reactive aldehyde species (RASP) RASP inhibitor (small molecule) ADX-629 Aldeyra asthma 
TNF TNFR:Fc etanercept Sobi asthma 2, * 
TNF chimeric MoAb infliximab MSD asthma 2, * 
TNF human MoAb golimumab Centocor asthma 2, * 
TargetApproachNameCompanyPatientsStatus/clinical phase
IgE 
IgE (Cε3 domain-site involved in binding to FcRI) humanized IgG1 MoAb omalizumab Novartis Asthma
urticaria
CRSwNP 
approved 
IgE (Cε3 domain) humanized MoAb ligelizumab Novartis asthma
urticaria 
IgE (M1 segment) humanized MoAb quilizumab Genentech asthma 
IgE (Cε3 domain) humanized MoAb MEDI4212 MedImmune LLC Asthma 
CεmX domain of membrane-bound IgE humanized MoAb FB825 Oneness Biotech Co Asthma 
IL-4/IL-13 
IL4Ra (subunit common to IL-4 and IL-13 receptors human MoAb dupilumab Regeneron/Sanofi atopic dermatitis
asthma CRSwNP
EoE 
approved 
IL-4+IL-13 receptors recombinant IL-4 variant pitrakinra Aerovance atopic dermatitis
asthma 
IL-4+IL-13 2 MoAbs (VAK694+dectrecumab) QBX258 Novartis asthma 
IL-4R suman IgG2 MoAb AMG317 Amgen asthma 
IL-4 humanized MoAb pascolizumab GSK asthma 
IL-4 human MoAb VAK694 Novartis asthma, pollinosis 
IL-4 soluble recombinant IL-4R altrakincept Amgen asthma terminated 
IL-13 humanized MoAb lebrikizumab Lilly atopic dermatitis 
IL-13 human MoAb tralokinumab LeoPharma atopic dermatitis approved 
IL-13 humanized MoAb anrukinzumab Wyeth asthma 
IL-13 humanized MoAb GSK679586 GSK asthma 
IL-13 human MoAb dectrecumab (QAX576) Novartis eosinophilic esophagitis 
IL-13 receptor α1 subunit (IL-13Rα1) human MoAb ASLAN 004 Aslan Pharmaceuticals eczema 
IL-5 
IL-5 humanized IgG1 MoAb mepolizumab GSK asthma,
EGPA
HES
CRSwNP 
approved 
IL-5 humanized MoAb reslizumab Teva asthma approved 
IL-5Ralpha humanized MoAb benralizumab AstraZeneca asthma approved 
IL-5 long acting MoAb depemokimab GSK asthma 
Other molecules regulating T2 inflammation 
TSLP humanized MoAb tezepelumab AstraZeneca/Amgen asthma approved 
TSLP neutralizing antibody fragment (inhaled form) CSJ117 Novartis asthma 2b 
TSLP receptor human MoAb ASP7266 Upstream Bio asthma 
IL-33 MoAb tozorakimab/MEDI3506 AstraZeneca asthma 
IL-33 human MoAb itepekimab Regeneron/Sanofi asthma 
ST2 (IL-33R) MoAb astegolimab Hoffmann-La Roche asthma 2b 
IL-33R MoAb melrilimab (GSK3772847) GSK healthy subjects 
IL-25 MoAb ABM125 Abeome asthma 1/2 
Tryptase tetramers MoAb MTPS9579A Roche/Genetech astma 2a 
CRTh2(PGD2 receptor) antagonist (small molecule) fevipiprant QAW039) Novartis asthma terminated 
CRTh2(PGD2 receptor) antagonist (small molecule) setipiprant Actelion asthma 
IL-9 humanized MoAb enokizumab AstraZeneca/MedImmune asthma 
IL-22 human MoAb fezakinumab Rockefeller University atopic dermatitis 
IL-31 humanized MoAb nemolizumab Galderma atopic dermatitis 
CCR3 (eotaxin receptor) inhibitor (small molecule) GW766944 Glaxo asthma 
Singlec 8 humanized MoAb lirentelimab Allakos Inc. atopic dermatitis eosinophilic esophagitis and duodenitis 2, 3 
Potential targets in non T2 inflammation 
IL-17 humanized MoAb secukinumab Novartis asthma terminated, * 
IL-17RA human MoAb brodalumab Amgen asthma terminated 
C5 humanized MoAb eculizumab Alexion asthma 
CXCR2 receptor antagonist (small molecule) AZD5069 AstraZeneca asthma 
CXCR1/2 receptor antagonist (small molecule) SCH527123 MSD asthma 
IL-6 humanized MoAb tocilizumab Roche asthma small proof‐of‐concept clinical trial, * 
IL-1 rIL-1 receptor antagonist anakinra Sobi asthma 2, * 
IL-1 alpha human MoAb bermekimab Janssen atopic dermatitis 2b 
Reactive aldehyde species (RASP) RASP inhibitor (small molecule) ADX-629 Aldeyra asthma 
TNF TNFR:Fc etanercept Sobi asthma 2, * 
TNF chimeric MoAb infliximab MSD asthma 2, * 
TNF human MoAb golimumab Centocor asthma 2, * 

*) other indications have been previously approved (within rheumatology; inflammatory bowel disease, psoriasis, autoinflammatory diseases, etc)

Furthermore, benralizumab showed efficacy in patients with severe CRSwNP by decreasing nasal blockage score in a randomized placebo controlled study [229] Depemokimab, a long-acting anti-IL-5 monoclonal antibody, is currently being evaluated in phase III clinical trials in severe uncontrolled asthma with an eosinophilic phenotype (NCT04719832).

This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).